These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36221998)

  • 1. New Pharmacophore Fingerprints and Weight-matrix Learning for Virtual Screening. Application to Bcr-Abl Data.
    Rehioui H; Cuissart B; Ouali A; Lepailleur A; Lamotte JL; Bureau R; Zimmermann A
    Mol Inform; 2023 Jan; 42(1):e2200210. PubMed ID: 36221998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Anticancer Hybrid Molecules by Supervised Machine Learning Models and
    Melge AR; Parate S; Pavithran K; Koyakutty M; Mohan CG
    J Chem Inf Model; 2022 Feb; 62(4):1126-1146. PubMed ID: 35172577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors.
    Vrontaki E; Melagraki G; Voskou S; Phylactides MS; Mavromoustakos T; Kleanthous M; Afantitis A
    Mini Rev Med Chem; 2017; 17(3):188-204. PubMed ID: 28143387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore modeling of nilotinib as an inhibitor of ATP-binding cassette drug transporters and BCR-ABL kinase using a three-dimensional quantitative structure-activity relationship approach.
    Shukla S; Kouanda A; Silverton L; Talele TT; Ambudkar SV
    Mol Pharm; 2014 Jul; 11(7):2313-22. PubMed ID: 24865254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. vHTS, 3-D Pharmacophore, QSAR and Molecular Docking Studies for the Identification of Phyto-derived ATP-Competitive Inhibitors of the BCR-ABL Kinase Domain.
    Metibemu DS; Oyeneyin OE; Metibemu AO; Adeniran OY; Omotuyi IO
    Curr Drug Discov Technol; 2022; 19(2):e021221198480. PubMed ID: 34856909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations.
    Melge AR; Kumar LG; K P; Nair SV; K M; C GM
    J Biomol Struct Dyn; 2019 Nov; 37(18):4747-4766. PubMed ID: 30580670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Navigating pharmacophore space to identify activity discontinuities: A case study with BCR-ABL.
    Lejmi M; Geslin D; Bureau R; Cuissart B; Ben Slima I; Meddouri N; Borgi A; Lamotte JL; Lepailleur A
    Mol Inform; 2024 Aug; 43(8):e202400050. PubMed ID: 38979846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining pharmacophore fingerprints and PLS-discriminant analysis for virtual screening and SAR elucidation.
    Askjaer S; Langgård M
    J Chem Inf Model; 2008 Mar; 48(3):476-88. PubMed ID: 18281962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoprint: A Combination of a Pharmacophore Fingerprint and Artificial Intelligence as a Tool for Computer-Aided Drug Design.
    Warszycki D; Struski Ł; Śmieja M; Kafel R; Kurczab R
    J Chem Inf Model; 2021 Oct; 61(10):5054-5065. PubMed ID: 34547888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach.
    Huang TT; Wang X; Qiang SJ; Zhao ZN; Wu ZX; Ashby CR; Li JZ; Chen ZS
    Front Cell Dev Biol; 2021; 9():649434. PubMed ID: 33748144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How diverse are diversity assessment methods? A comparative analysis and benchmarking of molecular descriptor space.
    Koutsoukas A; Paricharak S; Galloway WR; Spring DR; Ijzerman AP; Glen RC; Marcus D; Bender A
    J Chem Inf Model; 2014 Jan; 54(1):230-42. PubMed ID: 24289493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
    Jain SK; Langdon WY; Varticovski L
    Oncogene; 1997 May; 14(18):2217-28. PubMed ID: 9174058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Virtual Screening Approach for the Identification of High Affinity Small Molecules Targeting BCR-ABL1 Inhibitors for the Treatment of Chronic Myeloid Leukemia.
    Sharda S; Sarmandal P; Cherukommu S; Dindhoria K; Yadav M; Bandaru S; Sharma A; Sakhi A; Vyas T; Hussain T; Nayarisseri A; Singh SK
    Curr Top Med Chem; 2017; 17(26):2989-2996. PubMed ID: 28828991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Descriptors you can count on? Normalized and filtered pharmacophore descriptors for virtual screening.
    Good AC; Cho SJ; Mason JS
    J Comput Aided Mol Des; 2004; 18(7-9):523-7. PubMed ID: 15729851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives.
    Cui J; Fu R; Zhou LH; Chen SP; Li GW; Qian SX; Liu S
    Bioorg Med Chem Lett; 2013 Apr; 23(8):2442-50. PubMed ID: 23473682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simple idea to generate fragment and pharmacophore descriptors and their implications in chemical informatics.
    Catana C
    J Chem Inf Model; 2009 Mar; 49(3):543-8. PubMed ID: 19243168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
    Carlesso N; Frank DA; Griffin JD
    J Exp Med; 1996 Mar; 183(3):811-20. PubMed ID: 8642285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase.
    Liedtke M; Pandey P; Kumar S; Kharbanda S; Kufe D
    Oncogene; 1998 Oct; 17(15):1889-92. PubMed ID: 9788431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study.
    Banavath HN; Sharma OP; Kumar MS; Baskaran R
    Sci Rep; 2014 Nov; 4():6948. PubMed ID: 25382104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats.
    Frank DA; Varticovski L
    Leukemia; 1996 Nov; 10(11):1724-30. PubMed ID: 8892675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.